LONDON (ShareCast) - (ShareCast News) - NetScientific's portfolio company, Vortex BioSciences, has been granted a critical patent on its core technology in the US.
The granted patent, licensed exclusively to Vortex from UCLA, was also recently issued in China and Australia and covers its core technology of inertial microfluidics and its application to the separation and collection of cells of interest including circulating tumour cells.

Vortex Biosciences is a cancer diagnostic instrument company providing liquid biopsy solutions for isolating, detecting and harvesting circulating tumour cells from cancer patients' blood sample for use in downstream clinical applications such as monitoring disease progression and drug treatment effectiveness.

Dr Michael Boyce-Jacino, head of US Operations at NetScientific said: "This key patent provides strong protection of our novel and powerful new platform technology for cell separation. Alongside our three previously issued patents, this US patent strengthens our global market position as we prepare to beta launch our VTX-1 product in the US later this year."

At 1126 BST, NetScientific shares were down 4.5% at 160p.

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE